OMER OMEROS CORP
Pharmaceutical Preparations · Nasdaq · SEC CIK 1285819 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY181.2%
TTM EPS YoY176.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR70.1%
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA45.4%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets136.3%
Debt / equity—
Current ratio2.27x
Interest coverage-1.47x
Cash quality & payout
Operating cash flow / net income-0.38x
Accruals ratio62.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $35.93M | $28.53M | $9.89M | — | $0 | $0 | $0 | — |
| Cost of revenue | $826,000 | $798,000 | $587,000 | — | $0 | $0 | $0 | — |
| Gross profit | $35.11M | $27.73M | $9.31M | — | $0 | $0 | $0 | — |
| R&D expense | $16.06M | $13.80M | $13.36M | $19.45M | $15.99M | $22.01M | $23.85M | $23.32M |
| SG&A expense | $14.55M | $13.86M | $13.37M | $9.63M | $10.40M | $10.35M | $11.12M | $12.34M |
| Operating income | $4.50M | $74,000 | -$17.42M | -$29.08M | -$26.39M | -$32.35M | -$34.97M | -$35.66M |
| Interest expense | $6.22M | $7.58M | $5.89M | $8.73M | -$13.36M | $15,000 | $3.65M | $3.18M |
| Pretax income | -$63.78M | $6.67M | $51.31M | $81.90M | -$21.24M | -$25.89M | -$37.56M | — |
| Income tax | $46,000 | $29,000 | $57,000 | $2.01M | $0 | $0 | $0 | — |
| Net income | -$57.36M | $13.23M | $56.06M | $86.45M | -$30.92M | -$25.42M | -$33.46M | -$31.36M |
| EBITDA | $4.70M | $274,000 | -$17.18M | -$28.85M | -$26.19M | -$32.15M | -$34.68M | -$35.36M |
| EPS (basic) | -0.79 | 0.18 | 0.78 | — | -0.47 | -0.43 | -0.58 | — |
| EPS (diluted) | -0.79 | 0.15 | 0.62 | — | -0.47 | -0.43 | -0.58 | — |
| Weighted avg. shares (diluted) | 72.98M | 89.63M | 90.12M | — | 66.26M | 58.59M | 58.06M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $5.07M | $1.99M | $1.91M | $9.66M | $2.40M | $1.90M | $4.26M | $3.40M |
| Short-term investments | $90.18M | $129.97M | $133.41M | $162.14M | $33.69M | $26.84M | $48.15M | $86.73M |
| Receivables | $16.10M | $11.71M | $6.75M | $0 | $6.91M | $6.28M | $7.08M | $7.74M |
| Inventory | $453,000 | $842,000 | $183,000 | $0 | — | — | — | — |
| Current assets | $150.89M | $185.24M | $180.35M | $215.67M | $71.81M | $69.65M | $96.18M | $134.12M |
| PP&E, net | $1.25M | $1.38M | $1.53M | $1.77M | $2.01M | $2.24M | $2.42M | $2.68M |
| Total assets | $248.09M | $286.83M | $286.17M | $325.63M | $185.71M | $200.57M | $235.16M | $277.08M |
| Current liabilities | $66.57M | $94.96M | $59.44M | $78.06M | $80.76M | $85.50M | $83.22M | $79.53M |
| Long-term debt | $31.89M | $42.03M | $52.81M | $51.36M | $154.94M | $154.94M | $164.94M | $164.90M |
| Total debt | $31.89M | $42.03M | $52.81M | $51.36M | $154.94M | $154.94M | $164.94M | $164.90M |
| Total liabilities | $338.07M | $338.18M | $349.51M | $446.86M | $406.18M | $429.25M | $448.71M | $459.69M |
| Shareholders' equity | -$89.97M | -$51.35M | -$63.33M | -$121.23M | -$220.48M | -$228.69M | -$213.55M | -$182.61M |
| Net debt | $26.82M | $40.04M | $50.90M | $41.70M | $152.54M | $153.03M | $160.68M | $161.50M |
| Shares outstanding | 74.23M | 72.09M | 72.00M | 71.67M | 70.07M | 60.02M | 58.06M | 58.04M |
| Cash flow statement | ||||||||
| Operating cash flow | $13.26M | $4.15M | -$14.51M | -$39.84M | -$18.47M | -$21.94M | -$35.84M | -$28.98M |
| Capital expenditure | $25,000 | $45,000 | $0 | $0 | $11,000 | $13,000 | $41,000 | $26,000 |
| Free cash flow | $13.23M | $4.10M | -$14.51M | -$39.84M | -$18.48M | -$21.95M | -$35.88M | -$29.01M |
| Investing cash flow | $39.76M | $3.40M | $28.73M | $111.55M | -$6.86M | $21.30M | $38.54M | $34.95M |
| Financing cash flow | -$49.93M | -$7.47M | -$21.98M | -$64.44M | $25.82M | -$1.72M | -$1.84M | -$4.09M |
| Depreciation & amortization | $200,000 | $200,000 | $239,000 | $235,000 | $200,000 | $200,000 | $289,000 | $301,000 |
| Stock-based compensation | $3.00M | $1.62M | $1.89M | $1.73M | $1.94M | $2.06M | $2.45M | $2.43M |
| Share buybacks | $0 | $5.73M | $4.15M | $0 | $0 | $0 | $0 | $0 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.